Rome, 10 mg. (beraking latest news Salute) – Between 27 December 2020 and 26 April 2021 for the four vaccines in use in the current vaccination campaign, 56,110 reports were received out of a total of 18,148,394 doses administered (with a reporting rate of 309 per 100,000 doses ), of which 91% refer to non-serious events, which resolve completely, such as pain at the injection site, fever, asthenia / fatigue, muscle aches. Serious reports, on the other hand, correspond to 8.6% of the total, with a rate of 27 serious events per 100,000 doses administered, regardless of the type of vaccine, the dose (first or second) and the possible causal role of vaccination. This is what emerges from the fourth Pharmacovigilance Report on Covid-19 vaccines published by the Italian Medicines Agency, relating to reports of suspected adverse reactions registered in the National Pharmacovigilance Network.
As reported in previous reports – reports AIFA – the reported events arise mainly on the same day of vaccination or the next day (85% of cases). Most of the reports are related to Pfizer / BioNTech’s Comirnaty * vaccine (75%), so far the most used in the vaccination campaign (70.9% of administered doses), and only to a lesser extent to AstraZeneca’s Vaxzevria * vaccine (22 %) and the Moderna vaccine (3%), while there are no reports, in the period considered, relating to Covid-19 Vaccine Janssen, J&J (0.1% of the doses administered).
The investigation at national level of these reports – recalls Aifa – is conducted with the support of a ‘Working Group for the evaluation of thrombotic risks from anti-Covid-19 vaccines‘, made up of some of the leading national thrombosis experts and hemostasis.
COPYRIGHT today © breaking latest news